ADCs approved by FDA sorted based on the year of their first approval
| ADC | Target | Disease with FDA approval | Approval year |
|---|---|---|---|
| Gemtuzumab ozogamicin | CD33 | Acute myeloid leukemia | 2000 |
| Brentuximab vedotin | CD30 | ALCL, CTCL, HL, MF, PTCL | 2011 |
| Trastuzumab emtansine | HER2 | Breast cancer | 2013 |
| Inotuzumab ozogamicin | CD22 | Lymphoblastic leukemia-lymphoma | 2017 |
| Moxetumomab pasudotox | CD22 | HCL | 2018 |
| Polatuzumab vedotin | CD79B | DLBCL | 2019 |
| Enfortumab vedotin | Nectin-4 | Urogenital cancer | 2019 |
| Trastuzumab deruxtecan | HER2 | Breast cancer, gastric cancer | 2019 |
| Sacituzumab govitecan | Trop-2 | Breast cancer, urogenital cancer | 2020 |
| Belantamab mafodotin | BCMA | Multiple myeloma | 2020 |
| Loncastuximab tesirine | CD19 | DLBCL | 2021 |
approved as monotherapy; ALCL: anaplastic large cell lymphoma; BCMA: B cell maturation antigen; CTCL: cutaneous T cell lymphoma; DLBCL: diffuse large B cell lymphoma; HCL: hairy cell leukemia; HER2: human epidermal growth factor receptor 2; HL: Hodgkin’s lymphoma; MF: mycosis fungoides; PTCL: peripheral T cell lymphoma